Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TA99-IL2
- Development stage
- Preclinical
- Lead developer
- ETH Zurich
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
TA99-IL2 is an immunocytokine consisting of the TA99 monoclonal antibody fused to interleukin-2 (IL2). The TA99 antibody component specifically targets gp75 (also known as tyrosinase-related protein 1 or TYRP1), a conserved tumor-associated antigen highly expressed in melanoma cells. By delivering IL2 directly to the tumor microenvironment, TA99-IL2 aims to recruit and activate immune effector cells, particularly natural killer (NK) cells, thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC) against established solid tumors. This therapeutic candidate was developed by researchers at ETH Zürich to overcome the limited efficacy of naked antibodies in immunosuppressive tumor environments.
- Other names
- TA99-interleukin-2TA-99-interleukin-2TA 99-interleukin-2TA99-IL-2TA-99-IL-2TA 99-IL-2
02
Targets
IL2RB (IL-2 receptor beta chain)C1Q (Complement C1q)TYRP1 (Tyrosinase-related protein 1)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on TA99-IL2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TA99-IL2.